Keith T. Demarest

Springhouse — United States

Psychology · Social Sciences

45h-index6.5kcitations178works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroendocrine regulation and behavior(26), Receptor Mechanisms and Signaling(25), Hypothalamic control of reproductive hormones(22), Diabetes Treatment and Management(20), Peroxisome Proliferator-Activated Receptors(19)

Publications177 total

Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB<sub>1</sub>R Inverse Agonists
ACS Medicinal Chemistry Letters·2020Open Access
5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors
Bioorganic & Medicinal Chemistry Letters·2020· 12 citedOpen Access
Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes
Bioorganic & Medicinal Chemistry Letters·2019· 5 citedOpen Access
Design, synthesis and structure activity relationships of indazole and indole derivatives as potent glucagon receptor antagonists
Bioorganic & Medicinal Chemistry Letters·2019· 20 citedOpen Access
6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB<sub>1</sub>) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity
Journal of Medicinal Chemistry·2018· 17 citedOpen Access
Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors
Bioorganic & Medicinal Chemistry Letters·2018· 12 citedOpen Access
Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents
Journal of Pharmacology and Experimental Therapeutics·2018· 28 citedOpen Access
Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors
Bioorganic & Medicinal Chemistry Letters·2018· 37 citedOpen Access
Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 Diabetes
ACS Medicinal Chemistry Letters·2017· 10 citedOpen Access
Evaluation of anti-diabetic effect and gall bladder function with 2-thio-5-thiomethyl substituted imidazoles as TGR5 receptor agonists
Bioorganic & Medicinal Chemistry Letters·2017· 19 citedOpen Access
Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
Annals of the New York Academy of Sciences·2015· 89 citedOpen Access
Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
PLoS ONE·2014· 70 citedOpen Access
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs
Bioorganic & Medicinal Chemistry Letters·2014· 6 citedOpen Access
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: Urea-based analogs
Bioorganic & Medicinal Chemistry Letters·2013· 6 cited
Beneficial Metabolic Effects of CB1R Anti-Sense Oligonucleotide Treatment in Diet-Induced Obese AKR/J Mice
PLoS ONE·2012· 17 citedOpen Access
A Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans
International Journal of Clinical Pharmacology and Therapeutics·2012· 4 cited
The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2
Journal of Lipid Research·2012· 114 citedOpen Access
Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
PLoS ONE·2012· 242 citedOpen Access
Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile
Bioorganic & Medicinal Chemistry Letters·2011· 51 citedOpen Access
Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
Diabetes Obesity and Metabolism·2011· 292 cited
page 1 of 9Next →

Frequent Co-authors

Yin Liang(10), Barbara R. Conway(9), Gail D. Riegle(8), Melville C. Osborne(7), Kenneth E. Moore(7), Kenneth E. Moore(7), Jun Xu(7), Gee‐Hong Kuo(7), Lubing Zhou(5), Lori Westover(5), David Polidori(4), Ellen V. Cryan(4), Patricia D. Pelton(4), William V. Murray(4), Han‐Cheng Zhang(4), Bruce E. Maryanoff(4), Joseph W. Gunnet(4), Sue Sha(3), Paul Rothenberg(3), Zhi‐Liang Chu(3)